



Kimia Biosciences Limited

Regd. Office/Works : Village-Bhondsi, Tehsil-Sohna, Distt. Gurugram (Haryana)
E-mail : compliance.kimia@gmail.com & info@kimiabiosciences.com
Web : www.kimiabiosciences.com | CIN NO. : L24239HR1993PLC032120
Tel. : +91 9654746544, 9654206544

February 14, 2022

Ref : KIMIABL/COMP/BSE/21-22/042

To
**Department of Corporate Affairs- Listing
BSE Limited**
PhirozJeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]

Sub: Outcome of Board Meeting held on Monday, February 14, 2022

Dear Sir,

Pursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have enclosed herewith:

1. Unaudited Financial Results for the third quarter and nine months ended December 31, 2021, duly approved and taken on record by the Board of Directors at its meeting held today i.e. Monday, February 14, 2022.
2. Limited Review Report on the aforesaid results from Statutory Auditors of the Company, as placed before the Board of Directors of the Company in its meeting held today.

The Board Meeting commenced at 02:00 p.m. and concluded at 6:40 p.m.

Kindly take the above information on your records.

Thanking You,
Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**

Sameer Goel
Managing Director

PLACE: New Delhi

Encl.: a/a



Independent Auditor's Review Report on Quarterly and nine months ended Unaudited Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended


To the Board of Directors of Kimia Biosciences Ltd.

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Kimia Biosciences Ltd. ("the Company") for the quarter and nine months ended December 31, 2021. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results read with notes therein, prepared in all material respects in accordance with the applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E



Place: Noida (Delhi – NCR)
Date: February 14, 2022


Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN : 22088926ACAQMW5724

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120


UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(Lakhs except EPS)

S. No.	Particulars	Quarter ended			Nine months ended		Year Ended
		31-12-21 (Unaudited)	30-09-21 (Unaudited)	31-12-20 (Unaudited)	31-12-21 (Unaudited)	31-12-20 (Unaudited)	31-03-21 (Audited)
I	Revenue from Operations	3,322.42	3,092.71	3,434.75	9,502.03	9,670.05	13,271.38
II	Other Income	21.79	32.14	55.41	71.32	198.52	245.62
III	Total Income (I+II)	3,344.21	3,124.85	3,490.16	9,573.35	9,868.57	13,517.00
IV	Expenses:						
	a) Cost of materials consumed	2,702.44	2,447.13	2,626.67	7,231.77	7,388.34	10,312.59
	b) Change in inventories of finished goods and work-in-progress	(146.91)	(183.50)	(98.13)	(280.20)	(527.93)	(627.22)
	c) Employee benefits expenses	405.39	368.56	395.23	1,139.15	1,030.48	1,409.10
	d) Finance costs	90.24	90.17	77.44	258.64	238.29	339.00
	e) Depreciation and amortisation expense	77.26	75.25	49.90	218.71	131.44	191.06
	f) Other expenses	366.36	496.39	322.59	1,312.10	933.09	1,339.03
V	Total Expenses (IV)	3,524.78	3,295.00	3,373.70	9,850.17	9,193.71	12,963.56
VI	Profit/(loss) Before Tax (IV-V)	(180.57)	(170.15)	116.46	(306.82)	674.86	553.44
VII	Tax expenses:						
	a) Current Tax	-	-	4.50	-	4.50	-
	b) Deferred Tax charge / (reversal)	(46.07)	(43.36)	69.31	(77.30)	69.31	43.00
VIII	Profit/(loss) for the period (VI-VII)	(134.50)	(126.79)	42.65	(229.52)	601.05	510.44
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
	- Remeasurement of defined benefit plans	-	-	-	-	-	(3.99)
B.	Items that will be reclassified to Profit or Loss (Net of Tax)						
X	Total Comprehensive Income for the period (VIII+IX)	(134.50)	(126.79)	42.65	(229.52)	601.05	506.45
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	Other Equity						1,370.52
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	(0.28)	(0.27)	0.09	(0.49)	1.27	1.08
	Diluted in Rs.	(0.28)	(0.27)	0.09	(0.49)	1.27	1.08

Other Notes

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The company has consider all possible impact of Covid-19 Pandemic in preparation of the above Financial Results. The company expects to recover the carrying amounts of its Assets & does not foresee any risk to service its financial obligation. The impact of any future events & developments emerging out of Pandemic, occurring after the approval of the above financial Results will be recognized prospectively.
- The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14.02.2022

 Date : February 14, 2022
 Place : New Delhi

FOR KIMIA BIOSCIENCES LIMITED

 Sameer Goel
 (Managing Director)
 DIN - 00161786
